ADMS - Adamas secures new patents for Gocovri and ADS-4101

Adamas Pharmaceuticals ([[ADMS]]) announces the issuance of two patents covering Gocovri (amantadine) extended-release capsules: U.S. Patent No. 11,065,213 issued on July 20, 2021, and U.S. Patent No. 11,077,073, projected to issue on August 3, 2021.These two patents are the first issued in this patent family and provide additional claims covering the drug product Gocovri, approved as the first and only drug to treat both dyskinesia and OFF motor complications in Parkinson’s patients, and methods of using GOCOVRI. With the issuance of these two patents, Adamas’ portfolio of patents for GOCOVRI now includes 17 U.S. patents that will expire from 2025 to 2038.These latest patents will be listed in the FDA Orange Book.Adamas previously announced settlement agreements with first filers for both available strengths of Gocovri, granting non-exclusive licenses from March 4, 2030, or earlier in certain circumstances.In addition, Adamas recently received a new patent covering ADS-4101, its investigational drug candidate being

For further details see:

Adamas secures new patents for Gocovri and ADS-4101